A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

NCT02973737 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

279

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Metastatic Breast Cancer

Interventions

DRUG: pyrotinib
DRUG: placebo
DRUG: Capecitabine

Sponsor

Jiangsu HengRui Medicine Co., Ltd.